The solid tumor testing market size is expected to see strong growth in the next few years. It will grow to $36.48 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of cancer, the expansion of healthcare infrastructure, the emergence of AI and IoT-based diagnostic devices, and increasing government initiatives in the field. Key trends expected in the forecast period include advancements in diagnostic tools, the introduction of nanocarrier-based therapies, strategic collaborations, and the development of next-generation testing devices.
The solid tumor testing market is anticipated to experience growth, driven by an increase in the prevalence of cancer. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, often in the form of solid tumors, remains a significant health concern. Solid tumor testing plays a crucial role in detecting cancer cells, even before they are visible on imaging tests. As of June 2023, a report from the Centers for Disease Control and Prevention revealed 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US in 2020. The escalating prevalence of cancer, with 403 new cases and 144 cancer-related deaths reported for every 100,000 people, is a key factor propelling the growth of the solid tumor testing market.
A notable contributor to the growth of the solid tumor testing market is the increasing healthcare expenditure. Healthcare expenditure, covering all expenses related to health services and diagnostics, has witnessed a notable rise. The growth in healthcare expenditure and supportive reimbursement policies for cancer diagnostics are significant drivers for the solid tumor testing market. Data from June 2023, released by the Centers for Medicare & Medicaid Services (CMS), revealed that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of the Gross Domestic Product (GDP). The substantial and continued growth in healthcare expenditure is expected to drive the solid tumor testing market.
A key trend in the solid tumor testing market is the emergence of innovative liquid biopsy test solutions. Major players in the market are actively engaged in developing liquid biopsy tests to enhance their market positions. In June 2020, NeoGenomics Inc., a US-based testing laboratory company, introduced a suite of three solid tumor liquid biopsy tests designed to detect cancer cells in the blood of patients with solid tumors. These tests offer non-invasive, early detection, and FDA-approved solutions, aiding in personalized treatment decisions with a quick turnaround time of seven days or fewer.
Companies in the solid tumor testing market are also focused on developing liquid biopsy platforms. These platforms utilize various technologies to analyze body fluids, typically blood, for cancer-related biomarkers. For instance, in January 2023, PrognomiQ, a US-based healthcare company, launched a multi-omics liquid biopsy platform. The platform is part of an ongoing prospective clinical program aiming to enroll 15,000 subjects, with a focus on leveraging multi-omics markers to distinguish between cancer and controls.
In June 2023, Quest Diagnostics, a US-based medical laboratory company, acquired Haystack Oncology Inc for $450 million. This acquisition is aimed at expanding access to liquid biopsy technology, strengthening research and development capabilities, and increasing market share in cancer diagnostics. Haystack Oncology Inc., an early-stage oncology company, specializes in developing solid tumor testing technology to improve outcomes for patients with cancer.
Major companies operating in the solid tumor testing market report are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.
North America was the largest region in the solid tumor testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the solid tumor testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The main types of solid tumor testing include genetic testing and conventional testing. Genetic testing is a medical test that examines an individual's DNA (genetic material) to identify changes or variations in genes, chromosomes, or proteins. This testing is applied in the treatment of various cancer types, including breast cancer, lung cancer, colorectal cancer, prostate cancer, and cervical cancer. Solid tumor testing serves various applications, including clinical and research purposes, and is utilized by diverse end-users such as hospitals, pharmaceutical and biotechnology companies, contract research organizations, and academic research institutions.
The solid tumor testing market research report is one of a series of new reports that provides solid tumor testing market statistics, including solid tumor testing industry global market size, regional shares, competitors with a solid tumor testing market share, detailed solid tumor testing market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor testing industry. This solid tumor testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The solid tumor testing market consists of revenues earned by entities by providing molecular profiling, next-generation sequencing, immunohistochemistry, fluorescence in situ hybridization (FISH), and biomarker testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Solid Tumor Testing Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on solid tumor testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for solid tumor testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Genetic Testing; Conventional Testing
2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Cervical Cancer
3) By Application: Clinical; Research
4) By End-Users: Hospitals; Pharmaceutical and Biotechnology Companies; Contract Research Organizations; Academic Research Institutions
Key Companies Mentioned: Johnson & Johnson Ltd; Roche Diagnostics Corporation; Thermo Fisher Scientific Inc.; Abbott Molecular Inc.; Becton Dickinson and Company (BD)
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Johnson & Johnson Ltd
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Molecular Inc.
- Becton Dickinson And Company (BD)
- Quest Diagnostics Incorporated
- Tosoh Corporation
- Agilent Technologies Inc.
- bioMerieux Inc.
- Beckman Coulter Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN GmbH
- Miltenyi Biotec GmbH
- Natera Inc.
- Myriad Genetics Inc.
- Novocure Inc.
- Invitae Corporation
- Guardant Health Inc.
- Foundation Medicine Inc.
- Epic Sciences Inc.
- Biocare Medical LLC
- Agena Bioscience Inc.
- Caris Life Sciences Inc.
- 20/20 Gene Systems Inc.
- Grail Inc.
- Avant Diagnostics Inc.
- Genomic Testing Cooperative
- Eutropics Pharmaceuticals Inc.
- Anixa Biosciences Inc.
- Cellular Biomedicine Group.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | February 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 27.78 Billion |
Forecasted Market Value ( USD | $ 36.48 Billion |
Compound Annual Growth Rate | 7.1% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |